The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH(2)(2+))[PtCl6].H2O and (RosH(2)(2+))(2)[PtCl6]Cl-2.4H(2)O
| Authors | |
|---|---|
| Year of publication | 2007 |
| Type | Article in Periodical |
| Magazine / Source | Polyhedron |
| MU Faculty or unit | |
| Citation | |
| Field | Inorganic chemistry |
| Keywords | Platinum(IV) complexes; Cytotoxicity; 6-Benzylaminopurine; Cytokinins; Bohemine; Roscovitine |
| Description | A series of Pt(IV) complexes with cytokinins or CDK-inhibitors derived from 6-benzylaminopurine (Bap) of the composition [Pt-IV(LH+)Cl-5] (1-14), where LH+ stands for protonated form of the Bap derivative (1-12), Boh = 6-(benzylamino)-2-[(3-hydroxypropyl)amino]-9-isopropylpurine, bohemine (13) and Ros = 6-(benzylamino)-2-[(1-hydroxymethylpropyl)amino]-9-isopropylpurine, roscovitine (14), have been prepared. They have been fully characterized by microanalysis, conductivity, FT-IR, H-1, C-13, N-15 and Pt-195 NMR and ES+ mass spectroscopy. All of the compounds have been tested in vitro for their cytotoxicity against four human cancer cell lines: malignant melanoma (G361), osteogenic sarcoma (HOS), chronic myelogenous erythroleukemia (K562) and breast adenocarcinoma (MCF7). The molecular structures of two ionic pair compounds (BohH(2)(2+))[PtCl6] center dot H2O (15) and (RosH(2)(2+))(2)[PtCl6]Cl-2 center dot 4H(2)O (16) have been determined by a single crystal X-ray analysis. |
| Related projects: |